Halozyme Therapeutics Inc. Common Stock vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while KraneShares Electric Vehicles and Future Mobility trades at $28.07 (market cap $72.36M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 173.9× KraneShares Electric Vehicles and Future Mobility's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and KraneShares Electric Vehicles and Future Mobility for 46 Days on average.
| HALO | KARS | |
|---|---|---|
Market Cap | $12.58B | $72.36M |
Volume | 2,179,278 | 5,034 |
Sector | Health | Sector/Thematic |
52-Week High | $115.22 | $38.01 |
52-Week Low | $61.63 | $27.25 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $14.49B | — |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →